Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) is scheduled to be announcing its earnings results before the market opens on Monday, March 18th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
Acurx Pharmaceuticals Stock Performance
Shares of ACXP stock opened at $2.91 on Monday. Acurx Pharmaceuticals has a one year low of $1.17 and a one year high of $8.82. The company’s 50-day moving average is $3.52 and its 200 day moving average is $3.30. The company has a market capitalization of $40.07 million, a price-to-earnings ratio of -2.77 and a beta of -1.87.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of Acurx Pharmaceuticals in a report on Wednesday, February 28th.
Hedge Funds Weigh In On Acurx Pharmaceuticals
Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in Acurx Pharmaceuticals by 235.2% during the fourth quarter. Vanguard Group Inc. now owns 406,387 shares of the company’s stock valued at $1,556,000 after purchasing an additional 285,143 shares in the last quarter. Northern Trust Corp bought a new position in Acurx Pharmaceuticals during the 4th quarter worth about $66,000. Osaic Holdings Inc. grew its holdings in Acurx Pharmaceuticals by 37.5% during the 2nd quarter. Osaic Holdings Inc. now owns 22,000 shares of the company’s stock worth $58,000 after acquiring an additional 6,000 shares in the last quarter. Finally, BlackRock Inc. lifted its position in shares of Acurx Pharmaceuticals by 149.8% during the first quarter. BlackRock Inc. now owns 16,699 shares of the company’s stock valued at $55,000 after buying an additional 10,014 shares during the last quarter. Hedge funds and other institutional investors own 11.28% of the company’s stock.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.
Featured Articles
- Five stocks we like better than Acurx Pharmaceuticals
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- MarketBeat Week in Review – 3/4 – 3/8
- Investing In Automotive Stocks
- What is a Microcap Stock? Everything You Need to Know
- How to Choose Top Rated Stocks
- How to Invest in Casino Stocks: Pros and Cons and More
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.